The lack of MTA phosphorylase in tumors leads to the accumulation of MTA in the tumor microenvironment, which has a negative impact on the immune function of various immune cells, including T cells and NK cells: MTA interferes with NK cells activating the PI3K/AKT/S6, MAPK/ERK, and NF‐κB pathways downstream of the CD16 receptor (Jacobs et al. 2020). Here, NFKB1 is linked to neoplasm.